Predictive value of antinuclear autoantibodies: The lessons of the systemic sclerosis autoantibodies

Autoimmunity Reviews

Volumn 7, Issue 8, 2008, Pages 588-593

  Koenig, Martial ^a   Dieudé, Mélanie ^a   Senécal, Jean Luc ^a  

^a Centre Hospitalier   (Canada)

Author keywords

Anti CENP B; Anti centromere; Anti RNA polymerase III; Anti Th To; Anti topoisomerase I; Autoantibodies; Scleroderma; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AUTOANTIGEN; BIOLOGICAL MARKER; CENTROMERE ANTIBODY; DNA DIRECTED RNA POLYMERASE III ANTIBODY; DNA TOPOISOMERASE ANTIBODY; ENZYME ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; ANTIBODY TITER; ANTIGEN SPECIFICITY; CELLULAR DISTRIBUTION; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; ETHNIC DIFFERENCE; GENETIC VARIABILITY; HUMAN; PHENOTYPE; PROGNOSIS; REVIEW; SYSTEMIC SCLEROSIS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; AUTOANTIGENS; BIOLOGICAL MARKERS; HUMANS; PROGNOSIS; SCLERODERMA, SYSTEMIC;

EID: 50949088213     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.autrev.2008.06.010     Document Type: Review

References (36)

1. Senécal J.L., Hénault J., and Raymond Y. The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis. J Rheumatol 32 (2005) 1643-1649
2. Walker J.G., and Fritzler M.J. Update on autoantibodies in systemic sclerosis. Curr Op Rheumatol 19 (2007) 580-591
3. Baroni S.S., Santillo M., Bevilacqua F., Luchetti M., Spadoni T., Mancini M., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354 (2006) 2667-2676
4. Douvas A.S., Achten M., and Tan E.M. Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma. J Biol Chem 254 (1979) 10514-10522
5. Shero J.H., Bordwell B., Rothfield N.F., and Earnshaw W.C. High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients. Science 231 (1986) 737-740
6. Koenig M., Fritzler M.J., Targoff I.N., Troyanov Y., and Senécal J.L. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 9 (2007) R78 doi: 10.11/ar2276
7. Dagher J., Voit R., Grummt I., Scheer U., Raymond Y., and Senécal J.L. Autoantibodies to NOR 90/hUBF: long-term clinical and serological followup from childhood to adulthood in a patient with limited systemic sclerosis suggests an antigen-driven immune response. J Rheumatol 29 (2002) 1543-1547
8. Ulanet D.B., Wigley F.M., Gelber A.C., and Rosen A. Autoantibodies Against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension. Arthritis Rheum (Arthritis Care & Research) 49 (2003) 85-92 No.1
9. Conrad K., Schössller W., Hiepe F., and Fritzler M.J. Autoantibodies in systemic autoimmune diseases. A diagnostic reference. Second Edition (2007), Pabst Science Publishers, Lengerich
10. Vázquez-Abad D., Grodzicky T., and Senécal J.L. Anticentromere antibodies in patients without Raynaud's disease or systemic sclerosis. Clin Immunol 90 (1999) 182-189
11. Vázquez-Abad D., Wallace S., Senécal J.L., Joyal F., Roussin A., Earnshaw W.C., et al. Anticentromere autoantibodies: evaluation of an ELISA using recombinant fusion protein CENP-B as antigen. Arthritis Rheum 37 (1994) 248-252
12. Yamasaki Y., Honkanen-Scott M., Hernandez L., Ikeda K., Barker T., Bubb M.R., et al. Nucleolar staining cannot be used as a screening test for the scleroderma marker anti-RNA polymerase i/iii antibodies. Arthritis Rheum 54 (2006) 3051-3056 No.9
13. Kuwana M., Okano Y., Pandey J.P., Silver R.M., Fertig N., and Medsger Jr. T.A. Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody. Analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum 52 (2005) 2425-2432
14. Reveille J.D., Solomon D.H., and the American College of Rheumatology ad hoc committee on immunologic testing guidelines. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Care Res 49 (2003) 399-412
15. Mitri G.M., Lucas M., Fertig N., Steen V.D., and Medsger T.A. A comparison between anti-Th/To and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement. Arthritis Rheum 48 (2003) 203-209
16. Harvey G.R., Butts S., Rands A.L., Patel Y., and McHugh N.J. Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol 117 (1999) 395-402
17. Steen V.D. Epidemiology and classification of scleroderma. In: Hochberg Silman M.C., Silman A.J., Smolen J.S., Weinblatt M.E., and Weisman M.H. (Eds). Rheumatoloy (2008), Mosby, Philadelphia 1361-1367
18. Scussel-Lonzetti L., Joyal F., Raynauld J.P., Roussin A., Rich É., Goulet J.R., et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 81 (2002) 154-167
19. Denton C.P., and Black C.M. Management of systemic sclerosis. In: Hochberg M.C., Silman A.J., Smolen J.S., Weinblatt M.E., and Weisman M.H. (Eds). Rheumatoloy (2008), Mosby, Philadelphia 1403-1415
20. Johnson S.R., Feldman B.M., and Hawker G.A. Classification criteria for systemic sclerosis subsets. J Rheumatol 34 (2007) 1855-1863
21. Steen V.D., Powell D.L., and Medsger Jr. T.A. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 31 (1988) 196-203
22. Perera A., Fertig N., Lucas M., Rodriguez-Reyna T.S., Hu P., Steen V.D., et al. Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 56 (2007) 2740-2746
23. Giordano M., Valentini G., Migliaresi S., Picillo U., and Vatti M. Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis. J Rheumatol 13 (1986) 911-916
24. Barnett A.J., Miller M.H., and Littlejohn G.O. A survival study of patients with scleroderma diagnosed over 30 years (1953-1983): the value of a simple cutaneous classification in the early stages of the disease. J Rheumatol 15 (1988) 276-283
25. Ferri C., Valentini G., Cozzi F., et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 81 (2002) 139-153
26. Diot E., Giraudeau B., Diot P., Degenne D., Ritz L., Guilmot J.L., et al. Is anti-topoisomerase I a serum marker of pulmonary involvement in systemic sclerosis?. Chest 116 (1999) 715-720
27. Steen V.D., and Medsger T.A. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 66 (2007) 940-944
28. Steen V.D. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 35 (2005) 35-42
29. Ioannidis J.P.A., Vlachoyiannopoulos P.G., Haidich A.B., Medsger Jr. T.A., Lucas M., Michet C.J., et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 118 (2005) 2-10
30. Bunn C.C., Denton C.P., Shi-Wen X., Knight C., and Black C.M. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 37 (1998) 15-20
31. Hesselstrand R., Scheja A., Shen G.Q., Wiik A., and Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology (Oxford) 42 (2003) 534-540
32. Jacobsen S., Halberg P., Ullman S., et al. Clinical features and serum autoantibodies in 230 Danish patients with systemic sclerosis. Br J Rheumatol (1998) 39-45
33. Meyer O.C., Fertig N., Lucas M., Somogyi N., and Medsger T.A. Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 34 1 (2007 Jan) 104-109
34. Kuwana M., Kaburaki J., Okano Y., Tojo T., and Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 37 (1994) 75-83
35. Simeon C.P., Armadans L., Fonollosa V., et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 42 (2003) 71-75
36. Vlachoyiannopoulos P.G., Dafni U.G., Pakas I., Spyropoulou-Vlachou M., Stavropoulos-Giokas C., and Moutsopoulos H.M. Systemic scleroderma in Greece: low mortality and strong linkage with HLA-DRB1*1104 allele. Ann Rheum Dis 59 (2000) 359-367